IFM Therapeutics

What IFM Therapeutics does

IFM Therapeutics is a privately-held biopharmaceutical company founded in 2015 and headquartered in Boston, Massachusetts, that develops first-in-class small molecule drugs targeting the innate immune system to treat inflammation-driven diseases and cancer. The company's scientific foundation is built on genetically-validated innate immune targets, including NLRP3, STING, cGAS, and AIM2, with programs spanning both agonism (for immuno-oncology) and antagonism (for inflammatory and autoimmune diseases). Its pipeline includes systemic, gut-directed, and CNS-penetrant NLRP3 antagonists, as well as STING and NLRP3 agonists.

The company operates through a distinctive subsidiary model whereby each program is housed in a dedicated, independently financed entity — IFM Uno (STING/NLRP3 agonists, acquired by Bristol-Myers Squibb in 2017 for up to $2.32B), IFM Tre (NLRP3 antagonists, acquired by Novartis in 2019 for up to $1.575B), IFM Due (cGAS-STING antagonists, acquired by Novartis in 2024 for up to $835M), and the active IFM Quattro and IFM Discovery entities. This architecture allows IFM to advance programs to proof-of-concept or early clinical stages before securing strategic exits or partnerships with large pharmaceutical companies.

Revenue is generated entirely through licensing, option, and acquisition transactions with pharmaceutical partners rather than through product sales. Headcount is 11–50 employees focused on central R&D, business development, and subsidiary management. Key investors include Atlas Venture, Abingworth, and Omega Funds. The company has progressed three novel programs from standing start into the clinic within its first 3.5 years and has received multiple industry awards, including the William B. Coley Award (2020) and Clarivate Deal of the Year (2017).

Name

IFM Therapeutics

Legal name

IFM Therapeutics, LLC

Website

https://ifmthera.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

IFM Therapeutics is a Boston-based private biopharmaceutical company founded in 2015 that develops first-in-class small molecule drugs targeting the innate immune system to treat inflammation-driven diseases and cancer, commercializing these programs through licensing and acquisition transactions with large pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Biopharmaceutical drug discovery and development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

Keywords

• Innate immune therapeutics
• Small molecule drug discovery
• Immuno-oncology drugs
• Autoimmune disease treatments
• Inflammatory disease therapy

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Acquisition/Option Exercise Payments: IFM develops subsidiary companies with specific drug programs, and large pharmaceutical companies acquire these subsidiaries or exercise options to acquire them. Payments include upfront payments upon closing and milestone payments upon achievement of development, regulatory, and sales milestones.
2. Venture Financing: IFM raises capital from venture capital investors including Omega Funds, Atlas Venture, and Abingworth to fund research and subsidiary development.
3. Collaboration and Option Agreement Payments: Novartis provides fixed payments to fully finance IFM Due's R&D costs in exchange for an option to acquire the subsidiary upon milestone achievements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

IFM Therapeutics is a privately-held biopharmaceutical company that discovers and develops first-in-class small molecule drugs targeting genetically-validated innate immune system targets for inflammation-driven diseases and cancer. The company operates through a unique subsidiary model in which each drug program is housed in its own dedicated, independently-financed subsidiary (e.g., IFM Uno, IFM Tre, IFM Due, IFM Quattro, IFM Discovery), advanced to proof-of-concept or early clinical stages, and then licensed or acquired by large pharmaceutical partners.

Product overview

IFM Therapeutics is a privately-held biopharmaceutical company that develops first-in-class small molecule drugs targeting the innate immune system. The company operates through a unique subsidiary model where each program is housed in its own dedicated, independently financed subsidiary: IFM Uno (STING/NLRP3 agonists for cancer, acquired by Bristol-Myers Squibb), IFM Tre (NLRP3 antagonists for inflammation, acquired by Novartis), IFM Due (cGAS-STING inhibitors for autoimmunity, acquired by Novartis), and IFM Quattro/IFM Discovery (emerging programs for inflammation and cancer). The company focuses on genetically-validated targets in the innate immune system to treat inflammation-driven diseases and cancer.

Differentiator

Problem solved

Functional benefit

Products and services

• NLRP3 and STING Agonist Programs (IFM Uno) Small-molecule agonist programs targeting NLRP3 and STING pathways to enhance innate immune response for cancer immunotherapy, developed for acquisition by pharma partners.
• NLRP3 Antagonist Programs (IFM Tre) Portfolio of small-molecule NLRP3 antagonists including IFM-2427/DFV890 systemic, gut-directed, and CNS-penetrant molecules for inflammatory and autoimmune diseases, including Phase 2 studies in FCAS, knee osteoarthritis, and coronary heart disease.
• cGAS-STING Pathway Antagonist Program (IFM Due) Small-molecule antagonists and inhibitors targeting the cGAS-STING pathway to treat serious inflammatory and autoimmune diseases through modulation of innate immune sensing of cytosolic DNA.
• IFM Quattro Subsidiary company developing next-generation small-molecule immunotherapies for inflammatory diseases and cancers, with ongoing preclinical and discovery programs in innate immunity.
• IFM Discovery Incubator entity tasked with discovering and developing additional novel targets within the innate immune system to support future subsidiary company launches.

Quantifiable outcome

• Three major acquisitions totaling over $4.7B in potential value achieved since 2017
• +1 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core.

• NovartiscoreStrategic or Co-development Partner · 13 March 2024Novartis exercised its option to acquire all outstanding capital stock of IFM Due, IFM's STING antagonist subsidiary, for up to $835M total consideration ($90M upfront + up to $745M milestones). This followed a four-year preclinical collaboration.
• NovartiscoreStrategic or Co-development Partner · 5 September 2019Collaboration and exclusive option agreement for IFM Due, IFM's cGAS-STING focused subsidiary. Novartis provides fixed payments to fully finance R&D costs in exchange for option to acquire IFM Due. Upon option exercise, IFM Due shareholders entitled to up to $840M in upfront and milestone payments. Novartis exercised this option in March 2024, acquiring IFM Due for $90M upfront plus up to $745M in milestones, totaling $835M.
• NovartiscoreStrategic or Co-development Partner · 1 April 2019Novartis acquired IFM Tre, IFM's NLRP3 antagonist subsidiary, for $310M upfront plus up to $1.265B in milestones, totaling $1.575B. The acquisition gave Novartis full rights to IFM Tre's portfolio including IFM-2427 and preclinical gut-directed and CNS-penetrant programs.
• Bristol-Myers SquibbcoreStrategic or Co-development Partner · 2 August 2017Bristol-Myers Squibb acquired IFM's STING and NLRP3 agonist programs for immuno-oncology. IFM received $300M upfront with potential of up to $1.01B in milestones for each program. This acquisition led to the formation of new IFM Therapeutics LLC which retained remaining research programs.

Scale indicators7 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• NodThera: NodThera is a clinical-stage biotech developing small-molecule NLRP3 inflammasome inhibitors for inflammatory and inflammatory-driven diseases. Directly comparable to IFM's NLRP3 antagonist programs (now at Novartis) and pursues the same genetically-validated target space.
• Olatec Therapeutics: Olatec Therapeutics develops small-molecule NLRP3 inflammasome inhibitors (e.g., dapansutrile) for inflammatory, autoimmune and metabolic diseases. Closely comparable to IFM Tre's NLRP3 antagonist franchise and competes for the same target class and indications.
• Inflazome: Inflazome was an Ireland-based biotech developing small-molecule NLRP3 inflammasome inhibitors for inflammatory diseases before being acquired by Roche in 2020. Directly comparable to IFM Tre as a peer in the NLRP3 antagonist category; included for its historical relevance even though no longer independent.

Broad incumbents

• Novartis: Novartis is a global pharmaceutical company that has acquired two IFM subsidiaries (IFM Tre for up to $1.575B in 2019 and IFM Due for up to $835M in 2024). Comparable as a broad incumbent in immunology/inflammation and the dominant counterparty in IFM's exit history.
• Bristol-Myers Squibb: Bristol-Myers Squibb is a global pharmaceutical company that acquired IFM Uno's STING and NLRP3 agonist programs for up to $2.32B in 2017. Comparable as a broad incumbent and key pharma acquirer for IFM's immuno-oncology programs.
• AbbVie: AbbVie is a global pharmaceutical company with active immunology and inflammasome (NLRP3) programs. Comparable as a broad incumbent with overlapping therapeutic focus and as a potential acquirer of small-molecule inflammation biotechs.
• Pfizer: Pfizer has invested in the NLRP3 inflammasome space (including a partnership with NodThera). Comparable as a broad incumbent in immunology with active deal-making interest in small-molecule innate immune modulators.
• Roche: Roche is a global pharmaceutical company that acquired Inflazome, a direct NLRP3 antagonist competitor to IFM Tre. Comparable as a broad incumbent that has invested in the same innate immune / inflammasome space and is a likely acquirer for similar biotech programs.

Emerging players

• Zai Lab: Zai Lab is a clinical-stage biopharmaceutical company focused on licensing and developing innovative therapeutics for immuno-inflammatory and oncology indications in China and globally. Comparable to IFM as a small-cap biotech pursuing licensing/in-licensing business model in immunology with multiple pharma partnerships.
• Casma Therapeutics: Casma Therapeutics is a biotechnology company developing autophagy-modulating therapeutics for inflammatory, autoimmune and rare diseases. Comparable to IFM as a privately-held biotech pursuing innate immunity/cellular clearance mechanisms with pharma-partnered and program-level business models.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/ifmthera
• Facebookfacebook.com/302551663590389

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries5 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IFM Therapeutics